Premium
Remoxipride in acute psychosis: Intramuscular followed by oral treatment compared to haloperidol, a doubleblind, multicenter trial
Author(s) -
Kahn JP.,
Laxenaire M.,
Burnat G.,
Albaret C.,
Holm AC.
Publication year - 1994
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470090201
Subject(s) - haloperidol , akathisia , brief psychiatric rating scale , extrapyramidal symptoms , medicine , somnolence , anesthesia , psychosis , adverse effect , schizophrenia (object oriented programming) , psychiatry , antipsychotic , dopamine
A double‐blind, randomized, multicentre study comparing the efficacy and safety of intramuscular (i.m.) remoxipride to that of i.m. haloperidol was undertaken in 119 psychotic patients (mean age: 37 ± 13.4 years). The study period was 1 week i.m., followed by 3 weeks of oral treatment. Dosage was 200–600 mg/day for remoxipride and 10–30 mg/day for haloperidol during i.m. and 150–600 mg/day for remoxipride and 10–40 mg/day for haloperidol during oral treatment. Both drugs produced marked clinical improvements during i.m. and oral treatment. During the i.m. week, the median Brief Psychiatric Rating Scale (BPRS) total score decreased from 51 to 34 in the remoxipride group and from 53 to 38 in the haloperidol group. Over the 4‐week treatment period, there was a significantly greater reduction in ‘some factors’ for remoxipride‐treated patients when compared to haloperidol‐treated patients. Somnolence was reported by 14% of haloperidol‐treated patients during i.m. treatment. Akathisia and tremor occurred significantly less in remoxipride‐treated patients as compared to haloperidol‐treated patients. Intramuscularly administered remoxipride is as effective as haloperidol in reducing acute phase psychotic symptoms, and is associated with fewer extrapyramidal symptoms.